Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,862 INR | -2.07% | +1.60% | -5.91% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 62% by 2026.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 44.69 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.91% | 1.82B | C- | ||
+26.08% | 88.38B | C+ | ||
-23.66% | 77.56B | B- | ||
+8.73% | 28.74B | C+ | ||
+7.45% | 18.45B | A- | ||
-13.80% | 16.57B | B | ||
+2.60% | 15.81B | A- | ||
+78.26% | 13.65B | C- | ||
+82.29% | 13.06B | C+ | ||
+3.66% | 12.61B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KIMS Stock
- Ratings Krishna Institute of Medical Sciences Limited